Edgewise Therapeutics (EWTX) CEO logs RSU vesting, sell-to-cover sales and 200,000 new options
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. President and CEO Kevin Koch reported multiple equity transactions on August 12, 2026. Previously granted RSUs converted into 17,969 and 21,875 shares of common stock, with a total of 17,971 shares sold in “sell-to-cover” trades solely to satisfy statutory tax withholding obligations, not as discretionary sales. Koch also received new awards of 100,000 RSUs, vesting in four annual installments beginning August 12, 2027, and 200,000 stock options with a $43.56 exercise price, vesting monthly over four years starting September 12, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
9 txns
Insider
KOCH KEVIN
Role
President and CEO
Sold
17,971 shs ($785K)
Approx. gross sale proceeds
$785K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F5 | 17,969 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F6 | 21,875 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F7 | 100,000 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F8 | 200,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 17,969 | $0.00 | $0.00 |
| Exercise | Common Stock | 21,875 | $0.00 | $0.00 |
| Sale | Common Stock F1, F2 | 8,782 | $43.6408 | $383K |
| Sale | Common Stock F1, F3 | 8,276 | $43.6582 | $361K |
| Sale | Common Stock F1, F4 | 913 | $44.33 | $40K |
Holdings After Transaction:
Restricted Stock Units — 201,563 shares (Direct);
Stock Option (Right to Buy) — 200,000 shares (Direct);
Common Stock — 52,488 shares (Direct)
Footnotes (8)
- F1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
- F2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $ 43.26 to $44.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.27, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.33 to $44.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
- F6. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
- F7. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
- F8. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Key Figures
RSUs vested to common stock: 17,969 shares
Additional RSUs vested: 21,875 shares
Shares sold to cover taxes: 17,971 shares
+3 more
6 metrics
RSUs vested to common stock
17,969 shares
RSUs converting into common stock on August 12, 2026
Additional RSUs vested
21,875 shares
RSUs converting into common stock on August 12, 2026
Shares sold to cover taxes
17,971 shares
Sell-to-cover transactions for statutory tax withholding on RSU vesting
New RSU grant
100,000 units
RSUs vesting in four annual installments beginning August 12, 2027
New stock options granted
200,000 shares
Options on common stock granted August 12, 2026
Stock option exercise price
$43.56 per share
Exercise price for 200,000 stock options expiring August 12, 2036
Key Terms
Restricted Stock Units ("RSUs"), sell-to-cover, statutory tax withholding obligations, Stock Option (Right to Buy)
4 terms
Restricted Stock Units ("RSUs") financial
"Restricted Stock Units ("RSUs") granted to the reporting person"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
sell-to-cover financial
"obligations to be funded by a "sell-to-cover" transaction"
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
statutory tax withholding obligations financial
"shares sold to cover the statutory tax withholding obligations"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
FAQ
What equity awards did Edgewise Therapeutics (EWTX) CEO Kevin Koch receive?
Kevin Koch received 100,000 RSUs and 200,000 stock options on August 12, 2026. The RSUs vest annually starting August 12, 2027, while the options, with a $43.56 exercise price, vest monthly over four years beginning September 12, 2026.
What RSU vesting activity did Edgewise Therapeutics (EWTX) report for its CEO?
Previously granted RSUs vested into 17,969 and 21,875 Edgewise Therapeutics common shares on August 12, 2026. A portion of these vested shares was then sold in “sell-to-cover” transactions to satisfy tax withholding obligations.
What are the terms of the new Edgewise Therapeutics (EWTX) stock options granted to the CEO?
Kevin Koch was granted stock options on 200,000 shares of common stock at a $43.56 exercise price. The options vest in equal monthly installments (1/48th each month) starting September 12, 2026, and expire on August 12, 2036.
Are the Edgewise Therapeutics (EWTX) CEO’s stock sales under a trading plan?
The Form 4’s Rule 10b5-1 checkbox is not marked, and footnotes describe the sales as sell-to-cover for statutory tax withholding on RSU vesting, indicating they were for tax obligations rather than discretionary trading.
AI-generated analysis. How Rhea-AI works. Not financial advice.
